IL1B and familial cold autoinflammatory syndrome: Canakinumab, a monoclonal antibody targeting IL-1β, has been approved by the FDA for treating autoimmune conditions such as familial cold autoinflammatory syndrome and Muckle–Wells syndrome [74].